Brigham and Women's Hospital uncovered a stark finding in a study published June 7: Prices for new drugs at launch rose 20 percent each year between 2008 and 2021.

Compared to the company's original two-shot vaccine results, Moderna found a "superior neutralizing antibody response" in its booster bivalent candidate targeting the COVID-19 omicron strain. 

An FDA committee of 21 independent advisers with one absentee unanimously voted to authorize the Novavax COVID-19 vaccine for emergency use in adults June 7, The Washington Post reported. 

At-home COVID-19 treatment Paxlovid was inaccessible to more than 26 million Americans January through March, according to a recent GoodRx analysis. The pharmacy "deserts" spanned 42 percent of the nation's counties and mainly fell in rural areas.

Johnson & Johnson and Emergent BioSolutions pointed blame at each other June 6 for breaking agreements in a COVID-19 vaccine supply contract, according to the Wall Street Journal. 

California is taking aim at high insulin prices with its own drug label, CalRx, with "below-market prices," the Los Angeles Times reported June 6. If fulfilled, the state will be the first to challenge the pharmaceutical industry.

State regulators have suspended the licenses of several leaders at Cheshire Medical Center in Keene, N.H., as they investigate how more than seven gallons of fentanyl went missing from the hospital across a four-month period. On June 29, the hospital will find out whether the state's pharmacy board is suspending or revoking its pharmacy permit. 

Medical technology company Becton, Dickinson and Co. plans to shell out more than $1.5 billion in cash for Parata Systems, an organization with a $600 million stake in the pharmacy automation market.

The U.S. discarded 82.1 million COVID-19 vaccine doses from December 2020 through mid-May, according to CDC data shared with NBC News. 

Global pharmaceutical company Bristol Myers Squibb is teed up to acquire Turning Point Therapeutics for $76 per share by the end of the third quarter. 

A lack of federal funding to secure more COVID-19 therapeutics and bring new drugs to market is spurring concern the nation could run out of key medications ahead of a potential fall surge. 

The FDA said Novavax's COVID-19 vaccine is effective, but the regulator raised concerns about potential heart risks associated with the shot in briefing documents released June 3, according to The Wall Street Journal.

The American Pharmacists Association named Ilisa Bernstein, PharmD, as the organization's interim CEO, effective immediately. 

The following 10 hospitals, health systems and hospital operators have posted job listings seeking pharmacy leaders in the last week.

Pfizer on June 1 said it has completed its application for emergency use authorization from the FDA for its three-dose COVID-19 vaccine in children under 5, The Wall Street Journal reports. 

Nephron Pharmaceuticals is recalling 2 million drug products spanning 20 product lines over concerns they might not be properly sterilized, The State reported June 1.

Americans often shell out extra for generics due to hazy pricing practices from pharmacy benefit managers and other middlemen, according to a new report from researchers at the USC Schaeffer Center in Los Angeles. 

GSK entered a definitive agreement May 31 to purchase Affinivax, a clinical-stage, Boston-based biopharmaceutical company, for $2.1 billion and up to $1.2 billion in potential development milestones.

The FDA withdrew approval for umbralisib, a medication used to treat marginal zone lymphoma and follicular lymphoma, over safety concerns June 1.

Pfizer's COVID-19 antiviral Paxlovid has become the most-prescribed at-home COVID-19 treatment in the U.S., The Wall Street Journal reported May 30.